06086 FANGZHOU JIANKE
- 5.400
- -0.900-14.29%
FANGZHOU JIANKE News
Stock market anomaly: Ark Pharmacy (06086) rebounded more than 20% on the second day of listing, still falling by 30% compared to the IPO price. It has accumulated losses of nearly 0.9 billion yuan in the past three years.
According to the Zhītōng Cáijīng app, Ark Pharmacy (06086) fell over 44% yesterday and rebounded over 20% in early trading today. The current stock price still fell 30% from the offer price. As of press time, it rose 17%, to HKD 5.3, with a turnover of HKD 11.1438 million. It is reported that Ark Pharmacy focuses on the management of chronic diseases (such as hypertension, cardiovascular, respiratory system, etc.), provides comprehensive and all-round management services for chronic diseases, and provides comprehensive medical services and online retail pharmacy services through the Jianke platform. According to the information from Zhuó Shí Zīxún, based on the average monthly active users in 2023, the company is China's largest online chronic disease management platform.
Why can't Farlong Pharmaceuticals (06086) tell the story of H2H despite the dark market crash and the waist-cutting of the listing?
Wearing the title of "the largest internet plus-related chronic disease management platform in China", Ark Pharmacy (06086) officially listed on the Hong Kong Stock Exchange on July 9th. However, this title seems to have brought little benefit to the company, as the opening price dropped by nearly 50%, showing the "other passion" from the capital markets.
Hong Kong stocks closed (07.09) | HSI flat, Apple suppliers and semiconductor stocks strong throughout the day, cnbm (03323) plummeted 13% after warning of earnings.
In the morning trading, the three major Hong Kong stock indices showed weak volatility. They all rose and turned red at noon, but then struggled to rise. The Hang Seng Index and the National Index successively fell, only the Hang Seng China Enterprise Index achieved growth.
Arctic Vision's IPO First Offer Price is HKD 4.68, 42.79% lower than the offer price.
Kingwu Finance | Ark Cloud Health (06086) debuted at HK$4.68, a 42.79% discount to the offer price, with a pre-market turnover of 3.1385 million shares and a turnover of HK$15.2637 million, excluding handling fees. Each hand consists of 500 shares, resulting in a book loss of HK$1,750. According to the previous offer results, the price was set at HK$8.18 per share, with a total capital-raising amount of HK$1.95 billion and a net amount of approximately HK$67.09 million. Each hand consists of 500 shares, with a 40.04% chance of winning one hand when subscribing for four hands. During the Hong Kong public offering stage, 4,371 valid applications were received for subscription, which was 16.63 times the subscription amount; international distribution was
On the first day of the new stock, Ark Pharmacy (06086) was listed and opened at 42.79% lower in the morning.
According to the news from CITIC Securities News APP, Ark Pharmacy (06086) has gone public. The announcement shows that the price per share is HKD 8.18, a total of 23.8 million shares are issued, and 500 shares per lot. The net amount raised is approximately HKD 67.09 million. As of the time of writing, the stock has fallen by 42.79%, to HKD 4.68, with a trading volume of HKD 15.2637 million. According to the information from Zhuo Shi Consulting, the group is the largest online platform for chronic disease management in China based on the average monthly active users in 2023. The group focuses on chronic disease management to meet the needs of patients with chronic diseases such as hypertension, cardiovascular, and respiratory syste.
Fangzhou Shares Down 43% in Pre-Market Session on HK Debut
Fangzhou Shares Down 43% in Pre-Market Session on HK Debut
Noah Health prices each share at HKD 8.18, and the public offering received 16.63 times oversubscription.
Fangyuan Healthy (06086) announced the distribution results, with a global issuance of 23.8 million shares, of which 30% is publicly offered in Hong Kong and 70% is internationally offered. The final offer price is HKD 8.18 per share, and the global net proceeds are approximately HKD 670.9 million. Trading of the expected shares in lots of 500 will begin at 9:00 am on Tuesday, July 9, 2024, at the Hong Kong Stock Exchange. The Hong Kong public offering received 16.63 times oversubscription, and the international offering received 1.66 times oversubscription.
New Stock Announcement | Each share of Ark Pharmacy (06086) is priced at HKD 8.18, with a public offering subscription rate of 16.63 times.
Foresight Williams Pharmacy (06086) announced the results of the distribution. The company globally issued 23.8 million shares, with 30% of the shares publicly offered in Hong Kong and 70% internationally. The final issue price was HKD 8.18 per share, and the net proceeds from the global issuance were approximately HKD 670.9 million. 500 shares per lot, expected to be traded on the Hong Kong Stock Exchange at 9:00 am on July 9, 2024 (Tuesday). Among them, the Hong Kong public offering received 16.63 times oversubscription, and the international offering received 1.66 times oversubscription.
The IPO issue price for Noah Health (06086.HK) in Hong Kong was set at HK8.18 per share, with a net raise of HK67.09 million.
On July 8, GL Medical announcement that Ark Pharmacy (06086.HK) sold a total of 23.8 million shares globally at HKD 8.18 per H stock, with a net amount of HKD 67.09 million. The number of shares sold in Hong Kong accounts for 30.00% of the global sales, with a subscription rate of 16.63 times; the number of shares sold internationally accounts for 70.00% of the global sales, with a subscription rate of 1.66 times. Assuming the Hong Kong public offering becomes unconditional on Tuesday, July 9, 2024, at 8 am (Hong Kong time), it is expected that the shares will be available at 9 am the same day.
Express News | Fangzhou - Final Offer Price Under Global Offering of HK$8.18 per Offer Share
New stock dark market | Ark Pharmacy (06086) fell more than 29% in the initial dark market trading, losing HK$1,190 per lot.
Ark Pharmacy (06086) will be listed in Hong Kong on July 9th (Tuesday).
Zhitong Hong Kong Stock Investment Journal | July 5th
Hong Kong Stock Investment Log | July 5, 2024
WiseInvestment Hong Kong Stock Investment Log | July 4th
Hong Kong stock market investment journal | July 4, 2024
Understanding the Ark Pharmacy (06086.HK) IPO with one chart.
Pharmacy chain Fangkuai Health is expected to start trading on the Hong Kong Stock Exchange main board on July 9, 2024.
China Briefing HK Stock Investment Journal|July 2nd
Hong Kong stock investment diary | July 2, 2024
Zhitoon Hong Kong Stock Investment Diary | July 1
Hong Kong Stock Investment Journal | July 1, 2024
New share announcement | The largest online chronic disease management platform, Ark Pharmacy (06086), will begin to solicit shares today and is expected to be listed on July 9th.
On June 28, 2024 to July 4, 2024, Jianke Ark (06086) will be listed, with a planned global offering of 23.8 million shares, of which 10% will be offered in Hong Kong and 90% will be offered internationally, with an additional 15% over-allotment option. The offering price per share is HKD 7.6-8.36, and each lot is 500 shares. The expected shares will start trading on the Stock Exchange of Hong Kong on July 9, 2024 (Tuesday) at 9:00 am.
Ark Pharmacy (06086.HK) plans to issue 23.8 million shares globally and is expected to be listed on July 9.
On June 28, Gelonghui announced that Arkpharmark (06086.HK) plans to issue a total of 23.8 million shares globally, with 2.38 million shares sold in Hong Kong, 21.42 million shares sold internationally, and an additional 15% over-allotment option. From June 28 to July 4, 2024, the company will be open for subscription, with the pricing date expected to be July 5. The sale price will be HKD 7.60-8.36 per share, with a trading unit of 500 shares per hand. Citigroup and Agricultural Bank of China International are joint sponsors. The expected listed date is July 9, 2024, on the main board of the Hong Kong Stock Exchange. According to data from Zhuoshi Consulting, the company had a flat performance in 2023.
Analysis
Price Target
No Data
